MARKET WIRETradingView • 14h ago
JIN MEDICAL INTERNATIONAL LTD. Estimates – NASDAQ:ZJYLTradingView report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
Why ZJYL Stock surged +26.34% Today — RQD Quant Desk Flash
$2.35 +26.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.46
JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $294.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZJYL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZJYL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ: ZJYL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.35 (+26.34% 1D, market cap $294.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ZJYL ranks #634 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZJYL compare to SMTI and INGN in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), ZJYL carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 29.2%, and ROIC of —. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and INGN (Inogen Inc) posts a D- grade (36/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZJYL?
▼
Per ZJYL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001837821), JIN MEDICAL INTERNATIONAL LTD. (Class A) generated $20.7M in revenue (-12.0% YoY), $1.2M in net income, and -$3.7M in free cash flow against $53.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.46 (+4.55%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZJYL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY ZJYL SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (36% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 29.2% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.20-4.1% Next Q
28
Q2 (-2Q)Grade E$2.11-8.1% Next Q
31
Q3 (-1Q)Grade E$1.94+21.1% Next Q
33
CurrentGrade D-$2.35-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZJYL Turnaround Squeeze
While ZJYL currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.10) and Max Pain ($2.47) forces dealer call-delta covering toward $8.90.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZJYL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZJYL Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZJYL Stock surged +26.34% Today — RQD Quant Desk Flash
JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) surged +26.34% to $2.35, trading at 12% of its 52-week range ($1.53 – $8.48). Stretched risk/reward at current multiples (29% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($1.53 – $8.48) with RSI-14 at 44.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.35 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 29.2% gross margin and $0 annual free cash flow.
Live ZJYL Headlines & Catalysts
MARKET WIREStock Titan • 17h ago
An 80% stake transfer means Jin Medical (ZJYL) need not issue substitute shares.Stock Titan report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 20h ago
A wheelchair maker's products are exported to more than 90 countries and regions. Dealers discussed its new models.Stock Titan report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 23h ago
Jin Medical International (ZJYL) Ticks Up 1.49% to $2.05 as Buyers Hold the $1.95 Floor - Cumulative Volumehttps://www.dars.gov.et/ report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETipRanks • 1d ago
Jin Medical Finalizes Kangma Equity Transfer, Avoids Additional Share IssuanceTipRanks report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 21h ago
12 Health Care Stocks Moving In Monday's Pre-Market SessionGainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Friday's After-Market SessionGainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor Therapeutics
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Friday's Intraday SessionGainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
MARKET WIREYahoo • 15h ago
Jin Medical Showcases Innovation Across Four Global Industry Expos: Lightweight Rehabilitation Assistive Line Draws Broad Market AttentionJin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment announced today its steady expansi
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZJYL)
- ✓Walkthrough of ZJYL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZJYL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.00%▼ DESCENDING CHANNEL
2026-11-02O $1.90H $2.35L $1.86C $2.35VOL 1.6K
RES: $2.79SUP: $1.07SMA50: $2.10SMA200: $2.34
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZJYL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
40.9%/yr Implied 5Y Growth
vs. -12.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZJYL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZJYL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZJYL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZJYL)
Health Care Rank #634 of 1016
⚔️ SMTI vs ZJYL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZJYL vs. SMTI, INGN, AVR, AGPU)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) ranks #634 by composite RQD confidence (36/100, grade D-) and #520 by equity capitalization ($294.2M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with ZJYL at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZJYL
ACTIVE
JIN MEDICAL INTERNATIONAL LTD. (Class A) | D- | 36/100 | — | 29.2% | — | +26.34% | $294.2M | Benchmark Subject |
| SMTI Sanara MedTech Inc. | D+ | 55/100 | 8.1x | 92.7% | 16.3% | -0.26% | $302.4M | /smti-vs-zjyl → |
| INGN Inogen Inc | D- | 36/100 | 8.5x | 52.2% | -27.0% | -5.51% | $192.7M | /ingn-vs-zjyl → |
| AVR Anteris Technologies Global Corp. | E | 23/100 | — | 70.3% | -35.0% | -1.71% | $625.9M | /avr-vs-zjyl → |
| AGPU Axe Compute Inc. | D | 44/100 | — | — | -35.0% | -8.78% | $101.7M | /agpu-vs-zjyl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001837821In its most recent audited fiscal period (FY2025, filed 2025-09-30), JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) reported GAAP revenue of $20.7M (-12.0% vs. FY2024 revenue of $23.5M , and +4.4% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $2.9M, and free cash flow of -$3.7M (-175.6% YoY). On the balance sheet, ZJYL closed FY2025 with $53.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $20.7M | $1.2M | $2.9M | -$3.7M | $53.4M | — |
| FY2024 (FY) | 2024-09-30 | $23.5M | $3.7M | -$1.2M | -$1.4M | — | — |
| FY2023 (FY) | 2023-09-30 | $19.8M | $2.9M | $3.1M | $3.1M | — | — |
3. ZJYL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZJYL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ: ZJYL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.35 (+26.34% 1D, market cap $294.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ZJYL ranks #634 in composite RQD confidence.
How does ZJYL compare to SMTI and INGN in the Health Care sector?
Within the Health Care sector (Industrial Specialties), ZJYL carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 29.2%, and ROIC of —. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and INGN (Inogen Inc) posts a D- grade (36/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZJYL?
Per ZJYL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001837821), JIN MEDICAL INTERNATIONAL LTD. (Class A) generated $20.7M in revenue (-12.0% YoY), $1.2M in net income, and -$3.7M in free cash flow against $53.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZJYL trading relative to its 50-day, 200-day, and 52-week technical levels?
ZJYL last traded at $2.35 (+26.34% on volume of 3,686,386 shares), positioning the stock +11.90% above its 50-day simple moving average ($2.10) and +0.43% above its 200-day simple moving average ($2.34). Across its 52-week range of $1.53 to $8.48, ZJYL sits at the 11.8% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.06 to $2.64).
ZJYL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZJYL stock moving today?
Why ZJYL Stock surged +26.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (29% profit margin) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ZJYL — JIN MEDICAL INTERNATIONAL LTD. (Class A): What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ZJYL scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 0% and FCF yield of -1.27%. Investor implication: the business is not currently generating a return on invested capital or positive free cash flow, so there is no cash-yield cushion supporting the current price.
- Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar measures institutional accumulation and options positioning and scored near the bottom of its range. Investor implication: the rating's flow inputs show little evidence of institutional conviction. No holder data is present in the source data to add detail.
- Insider Conviction: 6 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. Investor implication: insider signal is weak in the rating's inputs.
- Macro Regime Fit: 5 / 20. Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is a factor. Investor implication: the rating does not credit the stock with a favorable macro-regime profile.
- Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. Investor implication: this is the highest-scoring pillar, indicating the balance sheet is the relative strength, though the Piotroski score of 4/9 signals mixed financial-health indicators.
Taken together, the rating frames a stock whose balance sheet is comparatively the least-weak element while its cash generation, institutional flow, and macro fit are all weak. Valuation tradeoffs are visible in the market data: EV/EBITDA is 47.1 per the market data section, which sits alongside an operating margin of 2.9% and a net margin of 5.8%, so the multiple is not supported by strong operating profitability in the reported figures. Upside drivers would need to come from improving cash conversion, which the FCF yield and recent FCF history do not yet show.
Business
Per the profile, ZJYL is a NASDAQ-listed issuer in the Health Care sector, Industrial Specialties industry. Per the recent news wire, the company's products are exported to more than 90 countries and regions, and the company manufactures wheelchairs, with dealers discussing its new models. The source data does not detail the customer base, revenue mix by product, or specific monetization model beyond this.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $20.7M | $0.6M | $1.2M | N/A | $-3.7M | N/A | N/A |
| FY 2024 | $23.5M | $3.6M | $3.7M | N/A | $-1.4M | N/A | N/A |
| FY 2023 | $19.8M | $2.9M | $2.9M | N/A | $3.1M | N/A | N/A |
Per the SEC financials, revenue declined from $23.5M in FY 2024 to $20.7M in FY 2025, and operating income fell from $3.6M to $0.6M over the same period. Net income of $1.2M in FY 2025 exceeded operating income of $0.6M, a gap the source data does not explain. Free cash flow was negative in both FY 2025 ($-3.7M) and FY 2024 ($-1.4M) after $3.1M in FY 2023. Per the market data, gross margin is 29.2%, operating margin 2.9%, and net margin 5.8%, with ROIC at 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9; the Debt/Equity ratio is 0.5, supporting the rating's forensic balance-sheet pillar, though cash and debt balances are not available in source data.
Recent Catalysts & News Wire Analysis
- Kangma equity transfer. Per the recent news wire, the company finalized a Kangma equity transfer and avoids additional share issuance. A separate headline describes an 80% stake transfer that removes the need to issue substitute shares. Both are flagged YELLOW (MARKET WIRE).
- Price action. Per the recent news wire, one report describes the stock ticking up 1.49% to $2.05 while buyers hold a $1.95 floor, while the market data section shows the stock at $1.86, down 2.1%. These figures come from different reports and timestamps.
- Product and export footprint. Per the recent news wire, products are exported to more than 90 countries and regions, and dealers discussed new models.
- Risk watch. One news item (labeled as a TradingView estimates report) carries a summary that is a non-company URL; its content is not usable as a catalyst. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. The main 2nd-order watch item an investor can draw from the provided data is the dependence on the Kangma equity transfer outcome referenced in the news wire, since the company's stated avoidance of substitute share issuance bears on dilution. Investors should also monitor whether declining revenue and operating income continue, given the negative FCF in the two most recent periods.
Open Questions
- What are the cash and debt balances, since both are listed as N/A in the financial history?
- What explains net income of $1.2M exceeding operating income of $0.6M in FY 2025?
- What are the EPS and P/E figures, which are not available in source data?
- What is the terms and timing of the Kangma equity transfer, and what is its effect on share count?
- Which price reference is current, given the news wire reports $2.05 and the market data reports $1.86?
ZJYL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 14h ago
JIN MEDICAL INTERNATIONAL LTD. Estimates – NASDAQ:ZJYL TradingView report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 17h ago
An 80% stake transfer means Jin Medical (ZJYL) need not issue substitute shares. Stock Titan report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 20h ago
A wheelchair maker's products are exported to more than 90 countries and regions. Dealers discussed its new models. Stock Titan report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 23h ago
Jin Medical International (ZJYL) Ticks Up 1.49% to $2.05 as Buyers Hold the $1.95 Floor - Cumulative Volume https://www.dars.gov.et/ report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TipRanks • 1d ago
Jin Medical Finalizes Kangma Equity Transfer, Avoids Additional Share Issuance TipRanks report covering JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 21h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
🟡 MARKET WIRE Benzinga • 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor Therapeutics
🟡 MARKET WIRE Benzinga • 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ZJYL Bull vs. Bear Conversation Board — What's Your Call at $2.35?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZJYL 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.64 (-11.8%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ZJYL (D- • RQD 36/100) a Buy at $1.86?
Welcome to the ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.41 (-24.2%)
Spot @ $1.86 Pump the brakes on ZJYL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ZJYL, but look at what you are paying: current EV/EBITDA multiples with 29.2% gross margins. Unless JIN MEDICAL INTERNATIONAL LTD. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.27 (+22.0%)
Spot @ $1.86 ZJYL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ZJYL, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $1.86 (52-wk range $1.53 - $8.48), any beat on forward guidance forces shorts and underweight funds to chase.